Early cancer drug data give Amgen hope it's 'cracked KRAS code'

Decades of research have failed to uncover a therapeutic answer to one of the most well-known genetic drivers of cancer. Yet Amgen thinks it's broken through with an early-stage drug that, in initial results presented Monday at the American Society of Clinical Oncology's annual meeting, spurred tumors to shrink in five of 10 lung cancer patients.

The therapy's target is KRAS, an oncogene known to be behind many lung, pancreatic and colorectal cancers.